Preventing post-thrombotic syndrome after deep vein thrombosis with perivascular anti-inflammatory agent delivery

Ended Project Grant Awarded Last action

Award ID
R41HL160434
Recipient
Awarding agency
Obligated
$899,034

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date
Originally
Funding
  • $599,356.00 Federal
  • $299,678.00 Non-federal
Place of performance
Emeryville, CA 94608, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Post-thrombotic syndrome (PTS) is a chronic debilitating condition characterized by limb swelling and discomfort, hyperpigmentation, skin ulcers, and impaired quality of life. IT occurs within 2 years of deep vein thrombosis (DVT) treatment in 50-60% of patients with iliofemoral thrombosis and in 30-50% of all DVT patients regardless of thrombosis location (1). Even with pharmacological catheter-directed thrombolysis (pcdt) or catheter- directed thrombectomy (CDT) as used in the most recent clinical trials (e.g. attract, cavent and cava), there remains a 40-50% rate of PTS. In the nhlbi/NIH-funded attract randomized trial, for example, pcdt did not reduce the incidence of PTS over 24 months, compared to control anticoagulation alone. In subgroup analysis, pcdt conferred reduced moderate-to-severe PTS in iliofemoral DVT (2,3), and no benefit when pcdt was administered after 8 days post-symptom onset (4). Overall, there remains a clear unmet need to expand the armamentarium of therapies beyond selective pcdt in reducing the clinical and economic burden of PTS. Post-thrombotic syndrome evolves from an interplay of multiple factors: fibrotic vein wall stiffening leading to damaged venous valves and subsequent valvular reflux, and continued obstruction of venous outflow due to thrombus persistence, leading to venous hypertension. Each of these outcomes can arise from venous inflammation, which is now considered a key in the process of deterioration to PTS after DVT treatment (5,6). Hypothetically, drugs with anti-inflammatory properties may therefore have the ability to prevent PTS (7-10). IT is further plausible that anti-inflammatory therapy may be more efficacious if delivered locally, concomitantly with catheter-directed clearance of thrombosis (e.g. pcdt/CDT). Mercator medsystems is the pioneer in local perivascular drug delivery, particularly with anti-inflammatory agents such as dexamethasone (a powerful, inexpensive glucocorticoid). Via the bullfrog® micro-infusion catheter platform (currently available to treat vessels of 2-8 MM diameter), mercator is developing a device to treat the larger iliofemoral veins, which will have diameter up to 20 MM. Localized anti-inflammatory agent delivery is proposed as a novel therapy to reduce the progression to PTS after DVT treatment. In this phase i sttr proposal, aim 1 will investigate the anti-inflammatory capability of perivascular dexamethasone delivery in a mouse model of DVT, and aim 2 will engineer a larger bullfrog® device for human use in up to 20 MM-diameter veins. After completion of this phase i project, the central hypothesis of locally delivered anti-inflammatory treatment of the vein wall post-DVT treatment will be investigated in large animals and human trials in phase II research.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $299,678 $0
Original award $299,678 $299,678

Quick answers

Who received award R41HL160434?

R41HL160434 was awarded to Mercator Medsystems, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 20, 2021.

How much is award R41HL160434 worth?

$899,034 has been obligated on R41HL160434: $599,356 in federal funding and $299,678 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login